Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A phase II, open label study to investigate the efficacy and safety of domatinostat in combination with avelumab in patients with advanced unresectable/metastatic Merkel Cell Carcinoma progressing on anti-PD(L)1 antibody therapy – the MERKLIN 2 study

    Summary
    EudraCT number
    2018-004788-30
    Trial protocol
    DE   ES   BE   NL   FR   IT  
    Global end of trial date
    26 Feb 2024

    Results information
    Results version number
    v1(current)
    This version publication date
    08 Feb 2025
    First version publication date
    08 Feb 2025
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    4SC-202-3-2018
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT04393753
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    4SC AG
    Sponsor organisation address
    Fraunhoferstr. 22, Planegg-Martinsried, Germany, 82152
    Public contact
    Corporate Communications, 4SC AG, 0049 897007630, public@4sc.com
    Scientific contact
    Clinical Operations, 4SC AG, 0049 897007630, MERKLIN2@4sc.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    20 Mar 2024
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    26 Feb 2024
    Global end of trial reached?
    Yes
    Global end of trial date
    26 Feb 2024
    Was the trial ended prematurely?
    Yes
    General information about the trial
    Main objective of the trial
    To investigate the anti-tumor efficacy of domatinostat in combination with avelumab in patients with advanced unresectable/metastatic Merkel cell carcinoma (MCC) progressing on anti-PD-(L)1 antibody monotherapy.
    Protection of trial subjects
    An independent Safety Review Committee (SRC) was implemented to regularly review the safety data of the study. The SRC reviewed selected safety and other relevant data across the clinical study at regular, pre-defined intervals with special attention to the first patients treated in the clinical study to confirm the safety of the treatment regimen and to continuously reassess the risk-benefit ratio of the study treatment. The SRC was asked to make recommendations about overall safety aspects, as well as continuation, modification or termination of the clinical study for safety concerns. Additionally, after the first 6 patients were enrolled in the study and received domatinostat and 2 infusions of avelumab, the SRC reviewed the safety data for these patients and recommended either continuing the study at the same dose level or reducing the dose of domatinostat, in case safety issues were identified. Before the start of a new treatment cycle, subjects were assessed including adverse events, physical examination, and measurement of hematological and biochemical parameters. Depending on the observed toxicities, the dose of domatinostat could be individually reduced by 50% of the total daily dose. Guidance was given in the study protocol concerning actions to be taken due to the observed toxicities (dose reduction, interruption, discontinuation). Subjects requiring more than one dose reduction had to be discontinued.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    13 Oct 2020
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Netherlands: 1
    Country: Number of subjects enrolled
    Belgium: 1
    Country: Number of subjects enrolled
    France: 5
    Country: Number of subjects enrolled
    Germany: 8
    Country: Number of subjects enrolled
    Italy: 4
    Worldwide total number of subjects
    19
    EEA total number of subjects
    19
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    8
    From 65 to 84 years
    10
    85 years and over
    1

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    Study participants were screened in 22 centers, in Belgium (1 center), France (4 centers), Germany (10 centers), Italy (4 centers), The Netherlands (2 centers), and Spain (1 center); 16 centers (1 in Belgium, 4 in France, 7 in Germany, 3 in Italy and 1 in the Netherlands) enrolled 19 patients in the study between 30-Oct-2020 and 23-Dec-2021.

    Pre-assignment
    Screening details
    Subjects were screened during a 28-day screening period, prior to the start of study drug. 30 subjects were screened from 13-Oct-2020 to 11-Jan-2022; 11 subjects were screening failures due to violation of inclusion or exclusion criteria (N=9), withdrawal of consent (N=1) or sponsor's decision (N=1).

    Period 1
    Period 1 title
    Overall trial (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Not applicable
    Blinding used
    Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Cohort 1
    Arm description
    Included subjects progressing on avelumab (anti-PD-L1 antibody).
    Arm type
    Experimental

    Investigational medicinal product name
    Domatinostat
    Investigational medicinal product code
    4SC-202
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Domatinostat was taken every day twice daily with a total daily dose of 400 mg/d, in fasting conditions (two hours prior and one hour after domatinostat intake) together with 200 mL of water.

    Investigational medicinal product name
    Avelumab
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Concentrate for solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Avelumab was given intravenously as a short-infusion over 60 minutes at a dose of 800 mg every 2 weeks corresponding to 4 vials each containing 200 mg avelumab.

    Arm title
    Cohort 2
    Arm description
    Included subjects progressing on any anti-PD-1 antibody.
    Arm type
    Experimental

    Investigational medicinal product name
    Domatinostat
    Investigational medicinal product code
    4SC-202
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Domatinostat was taken every day twice daily with a total daily dose of 400 mg/d, in fasting conditions (two hours prior and one hour after domatinostat intake) together with 200 mL of water.

    Investigational medicinal product name
    Avelumab
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Concentrate for solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Avelumab was given intravenously as a short-infusion over 60 minutes at a dose of 800 mg every 2 weeks corresponding to 4 vials each containing 200 mg avelumab.

    Number of subjects in period 1
    Cohort 1 Cohort 2
    Started
    17
    2
    Completed
    17
    2

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Cohort 1
    Reporting group description
    Included subjects progressing on avelumab (anti-PD-L1 antibody).

    Reporting group title
    Cohort 2
    Reporting group description
    Included subjects progressing on any anti-PD-1 antibody.

    Reporting group values
    Cohort 1 Cohort 2 Total
    Number of subjects
    17 2 19
    Age categorical
    Units: Subjects
        Adults (18-64 years)
    6 2 8
        From 65-84 years
    10 0 10
        85 years and over
    1 0 1
    Gender categorical
    Units: Subjects
        Female
    3 1 4
        Male
    14 1 15

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Cohort 1
    Reporting group description
    Included subjects progressing on avelumab (anti-PD-L1 antibody).

    Reporting group title
    Cohort 2
    Reporting group description
    Included subjects progressing on any anti-PD-1 antibody.

    Subject analysis set title
    Full Analysis Set
    Subject analysis set type
    Full analysis
    Subject analysis set description
    The Full Analysis Set (FAS) population includes all subjects who received at least one dose of study medication (domatinostat or avelumab).

    Primary: Objective Response Rate (ORR)

    Close Top of page
    End point title
    Objective Response Rate (ORR) [1]
    End point description
    Percentage of patients having a confirmed CR or PR according to RECIST v1.1. Assessment was done by radiological imaging and response evaluation according to RECIST v1.1 by the investigator. CT or MRI scans (CT preferred) were done every 8 weeks for the first 6 months and every 12 weeks thereafter. The same imaging technique as used at baseline/screening should be used throughout the study.
    End point type
    Primary
    End point timeframe
    Entire study participation
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Study was discontinued prematurely. Therefore only descriptive analysis of the data was performed: categorical variables were summarized using frequency tables showing the number and percentage of patients within a particular category.
    End point values
    Cohort 1 Cohort 2
    Number of subjects analysed
    17
    2
    Units: subjects
        Objective Response
    1
    0
        No Objective Response
    16
    2
    No statistical analyses for this end point

    Secondary: Disease Control Rate (DCR)

    Close Top of page
    End point title
    Disease Control Rate (DCR)
    End point description
    Proportion of patients with either an objective response (CR, PR) or stable disease (SD) according to RECIST v1.1.
    End point type
    Secondary
    End point timeframe
    Entire study participation
    End point values
    Cohort 1 Cohort 2
    Number of subjects analysed
    17
    2
    Units: subjects
        Disease Control
    7
    0
        No Disease Control
    10
    2
    No statistical analyses for this end point

    Secondary: Progression Free Survival (PFS)

    Close Top of page
    End point title
    Progression Free Survival (PFS)
    End point description
    Time from first dosing (day 1) to the date of progressive disease or death from any cause (whichever comes first).
    End point type
    Secondary
    End point timeframe
    From first dosing to progression or death
    End point values
    Full Analysis Set
    Number of subjects analysed
    19
    Units: days
    number (confidence interval 95%)
        25% Quartile
    51 (32 to 56)
        50% Quartile
    58 (49 to 115)
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    The period of observation for collection of adverse events extended from signing informed consent form until 90 days after last administration of study treatment.
    Adverse event reporting additional description
    At each visit, the investigator asked for well-being and AEs by using neutral and non-leading questions. Additionally, clinically significant changes from baseline physical examination or other safety assessments were recorded as AEs.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    23
    Reporting groups
    Reporting group title
    Cohort 1
    Reporting group description
    Subjects progressing on avelumab (anti-PD-L1 antibody)

    Reporting group title
    Cohort 2
    Reporting group description
    Subjects progressing on any anti-PD-1 antibody.

    Serious adverse events
    Cohort 1 Cohort 2
    Total subjects affected by serious adverse events
         subjects affected / exposed
    5 / 17 (29.41%)
    1 / 2 (50.00%)
         number of deaths (all causes)
    5
    2
         number of deaths resulting from adverse events
    0
    0
    General disorders and administration site conditions
    Pain
         subjects affected / exposed
    1 / 17 (5.88%)
    0 / 2 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Vomiting
         subjects affected / exposed
    1 / 17 (5.88%)
    0 / 2 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hepatobiliary disorders
    Immune-mediated hepatitis
         subjects affected / exposed
    1 / 17 (5.88%)
    0 / 2 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Respiratory failure
         subjects affected / exposed
    1 / 17 (5.88%)
    0 / 2 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Renal and urinary disorders
    Acute kidney injury
         subjects affected / exposed
    0 / 17 (0.00%)
    1 / 2 (50.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Haematuria
         subjects affected / exposed
    0 / 17 (0.00%)
    1 / 2 (50.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hydronephrosis
         subjects affected / exposed
    1 / 17 (5.88%)
    0 / 2 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Endocrine disorders
    Adenocorticotropic hormone deficiency
         subjects affected / exposed
    1 / 17 (5.88%)
    0 / 2 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    Pain in extremity
         subjects affected / exposed
    1 / 17 (5.88%)
    0 / 2 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Infections and infestations
    Dermo-hypodermitis
         subjects affected / exposed
    0 / 17 (0.00%)
    1 / 2 (50.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Erysipelas
         subjects affected / exposed
    1 / 17 (5.88%)
    0 / 2 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Sepsis
         subjects affected / exposed
    1 / 17 (5.88%)
    0 / 2 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 1%
    Non-serious adverse events
    Cohort 1 Cohort 2
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    17 / 17 (100.00%)
    1 / 2 (50.00%)
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Malignant ascites
         subjects affected / exposed
    1 / 17 (5.88%)
    0 / 2 (0.00%)
         occurrences all number
    1
    0
    Skin papilloma
         subjects affected / exposed
    1 / 17 (5.88%)
    0 / 2 (0.00%)
         occurrences all number
    1
    0
    Tumour pain
         subjects affected / exposed
    1 / 17 (5.88%)
    0 / 2 (0.00%)
         occurrences all number
    1
    0
    Vascular disorders
    Hypotension
         subjects affected / exposed
    1 / 17 (5.88%)
    0 / 2 (0.00%)
         occurrences all number
    1
    0
    General disorders and administration site conditions
    Asthenia
         subjects affected / exposed
    4 / 17 (23.53%)
    1 / 2 (50.00%)
         occurrences all number
    5
    1
    Fatigue
         subjects affected / exposed
    2 / 17 (11.76%)
    0 / 2 (0.00%)
         occurrences all number
    9
    0
    Impaired healing
         subjects affected / exposed
    1 / 17 (5.88%)
    0 / 2 (0.00%)
         occurrences all number
    1
    0
    Mucosal inflammation
         subjects affected / exposed
    1 / 17 (5.88%)
    0 / 2 (0.00%)
         occurrences all number
    1
    0
    Oedema peripheral
         subjects affected / exposed
    1 / 17 (5.88%)
    0 / 2 (0.00%)
         occurrences all number
    1
    0
    Pyrexia
         subjects affected / exposed
    1 / 17 (5.88%)
    1 / 2 (50.00%)
         occurrences all number
    1
    1
    Reproductive system and breast disorders
    Penile oedema
         subjects affected / exposed
    1 / 17 (5.88%)
    0 / 2 (0.00%)
         occurrences all number
    1
    0
    Testicular oedema
         subjects affected / exposed
    1 / 17 (5.88%)
    0 / 2 (0.00%)
         occurrences all number
    1
    0
    Respiratory, thoracic and mediastinal disorders
    Dyspnoea
         subjects affected / exposed
    4 / 17 (23.53%)
    0 / 2 (0.00%)
         occurrences all number
    5
    0
    Dyspnoea exertional
         subjects affected / exposed
    2 / 17 (11.76%)
    0 / 2 (0.00%)
         occurrences all number
    2
    0
    Haemoptysis
         subjects affected / exposed
    1 / 17 (5.88%)
    0 / 2 (0.00%)
         occurrences all number
    1
    0
    Pneumonitis
         subjects affected / exposed
    1 / 17 (5.88%)
    0 / 2 (0.00%)
         occurrences all number
    1
    0
    Rhinorrhoea
         subjects affected / exposed
    1 / 17 (5.88%)
    0 / 2 (0.00%)
         occurrences all number
    1
    0
    Psychiatric disorders
    Anxiety
         subjects affected / exposed
    1 / 17 (5.88%)
    1 / 2 (50.00%)
         occurrences all number
    1
    1
    Insomnia
         subjects affected / exposed
    1 / 17 (5.88%)
    0 / 2 (0.00%)
         occurrences all number
    1
    0
    Sleep disorder
         subjects affected / exposed
    1 / 17 (5.88%)
    0 / 2 (0.00%)
         occurrences all number
    1
    0
    Investigations
    Alanine aminotransferase increased
         subjects affected / exposed
    2 / 17 (11.76%)
    0 / 2 (0.00%)
         occurrences all number
    2
    0
    Aspartate aminotransferase increased
         subjects affected / exposed
    2 / 17 (11.76%)
    0 / 2 (0.00%)
         occurrences all number
    2
    0
    Blood alkaline phosphatase increased
         subjects affected / exposed
    1 / 17 (5.88%)
    0 / 2 (0.00%)
         occurrences all number
    1
    0
    Blood creatine phosphokinase increased
         subjects affected / exposed
    2 / 17 (11.76%)
    0 / 2 (0.00%)
         occurrences all number
    2
    0
    Blood creatinine increased
         subjects affected / exposed
    2 / 17 (11.76%)
    0 / 2 (0.00%)
         occurrences all number
    3
    0
    Blood urea increased
         subjects affected / exposed
    1 / 17 (5.88%)
    0 / 2 (0.00%)
         occurrences all number
    1
    0
    C-reactive protein increased
         subjects affected / exposed
    2 / 17 (11.76%)
    0 / 2 (0.00%)
         occurrences all number
    2
    0
    Gamma-glutamyltransferase increased
         subjects affected / exposed
    2 / 17 (11.76%)
    0 / 2 (0.00%)
         occurrences all number
    3
    0
    Glomerular filtration rate increased
         subjects affected / exposed
    1 / 17 (5.88%)
    0 / 2 (0.00%)
         occurrences all number
    1
    0
    Lipase increased
         subjects affected / exposed
    1 / 17 (5.88%)
    0 / 2 (0.00%)
         occurrences all number
    1
    0
    Platelet count decreased
         subjects affected / exposed
    2 / 17 (11.76%)
    0 / 2 (0.00%)
         occurrences all number
    2
    0
    Injury, poisoning and procedural complications
    Accidental overdose
         subjects affected / exposed
    1 / 17 (5.88%)
    0 / 2 (0.00%)
         occurrences all number
    1
    0
    Cardiac disorders
    Palpitations
         subjects affected / exposed
    1 / 17 (5.88%)
    0 / 2 (0.00%)
         occurrences all number
    1
    0
    Nervous system disorders
    Dysaesthesia
         subjects affected / exposed
    1 / 17 (5.88%)
    0 / 2 (0.00%)
         occurrences all number
    1
    0
    Dysgeusia
         subjects affected / exposed
    2 / 17 (11.76%)
    0 / 2 (0.00%)
         occurrences all number
    3
    0
    Headache
         subjects affected / exposed
    1 / 17 (5.88%)
    0 / 2 (0.00%)
         occurrences all number
    1
    0
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    4 / 17 (23.53%)
    0 / 2 (0.00%)
         occurrences all number
    4
    0
    Leukopenia
         subjects affected / exposed
    2 / 17 (11.76%)
    0 / 2 (0.00%)
         occurrences all number
    2
    0
    Lymphadenectomy
         subjects affected / exposed
    1 / 17 (5.88%)
    0 / 2 (0.00%)
         occurrences all number
    1
    0
    Lymphopenia
         subjects affected / exposed
    1 / 17 (5.88%)
    0 / 2 (0.00%)
         occurrences all number
    1
    0
    Thrombocytopenia
         subjects affected / exposed
    1 / 17 (5.88%)
    0 / 2 (0.00%)
         occurrences all number
    3
    0
    Ear and labyrinth disorders
    Vertigo
         subjects affected / exposed
    2 / 17 (11.76%)
    0 / 2 (0.00%)
         occurrences all number
    2
    0
    Gastrointestinal disorders
    Abdominal pain
         subjects affected / exposed
    2 / 17 (11.76%)
    0 / 2 (0.00%)
         occurrences all number
    3
    0
    Constipation
         subjects affected / exposed
    4 / 17 (23.53%)
    1 / 2 (50.00%)
         occurrences all number
    4
    1
    Diarrhoea
         subjects affected / exposed
    6 / 17 (35.29%)
    0 / 2 (0.00%)
         occurrences all number
    6
    0
    Gastrooesophageal reflux disease
         subjects affected / exposed
    2 / 17 (11.76%)
    0 / 2 (0.00%)
         occurrences all number
    2
    0
    Nausea
         subjects affected / exposed
    5 / 17 (29.41%)
    1 / 2 (50.00%)
         occurrences all number
    7
    1
    Pancreatitis
         subjects affected / exposed
    1 / 17 (5.88%)
    0 / 2 (0.00%)
         occurrences all number
    1
    0
    Periodontal disease
         subjects affected / exposed
    1 / 17 (5.88%)
    0 / 2 (0.00%)
         occurrences all number
    1
    0
    Vomiting
         subjects affected / exposed
    1 / 17 (5.88%)
    1 / 2 (50.00%)
         occurrences all number
    3
    1
    Skin and subcutaneous tissue disorders
    Dry skin
         subjects affected / exposed
    1 / 17 (5.88%)
    0 / 2 (0.00%)
         occurrences all number
    1
    0
    Papule
         subjects affected / exposed
    1 / 17 (5.88%)
    0 / 2 (0.00%)
         occurrences all number
    1
    0
    Pruritus
         subjects affected / exposed
    2 / 17 (11.76%)
    0 / 2 (0.00%)
         occurrences all number
    2
    0
    Rash
         subjects affected / exposed
    1 / 17 (5.88%)
    0 / 2 (0.00%)
         occurrences all number
    1
    0
    Rash erythematous
         subjects affected / exposed
    1 / 17 (5.88%)
    0 / 2 (0.00%)
         occurrences all number
    1
    0
    Renal and urinary disorders
    Dysuria
         subjects affected / exposed
    1 / 17 (5.88%)
    0 / 2 (0.00%)
         occurrences all number
    1
    0
    Haematuria
         subjects affected / exposed
    2 / 17 (11.76%)
    0 / 2 (0.00%)
         occurrences all number
    2
    0
    Hypertonic bladder
         subjects affected / exposed
    1 / 17 (5.88%)
    0 / 2 (0.00%)
         occurrences all number
    1
    0
    Polyuria
         subjects affected / exposed
    1 / 17 (5.88%)
    0 / 2 (0.00%)
         occurrences all number
    1
    0
    Urinary retention
         subjects affected / exposed
    1 / 17 (5.88%)
    0 / 2 (0.00%)
         occurrences all number
    1
    0
    Urinary tract obstruction
         subjects affected / exposed
    1 / 17 (5.88%)
    0 / 2 (0.00%)
         occurrences all number
    1
    0
    Endocrine disorders
    Hyperthyroidism
         subjects affected / exposed
    1 / 17 (5.88%)
    0 / 2 (0.00%)
         occurrences all number
    2
    0
    Hypothyroidism
         subjects affected / exposed
    2 / 17 (11.76%)
    0 / 2 (0.00%)
         occurrences all number
    3
    0
    Musculoskeletal and connective tissue disorders
    Arthralgia
         subjects affected / exposed
    1 / 17 (5.88%)
    0 / 2 (0.00%)
         occurrences all number
    1
    0
    Pain in extremity
         subjects affected / exposed
    2 / 17 (11.76%)
    0 / 2 (0.00%)
         occurrences all number
    2
    0
    Infections and infestations
    COVID-19
         subjects affected / exposed
    2 / 17 (11.76%)
    0 / 2 (0.00%)
         occurrences all number
    2
    0
    Diverticulitis
         subjects affected / exposed
    1 / 17 (5.88%)
    0 / 2 (0.00%)
         occurrences all number
    1
    0
    Herpes simplex
         subjects affected / exposed
    1 / 17 (5.88%)
    0 / 2 (0.00%)
         occurrences all number
    1
    0
    Localised infection
         subjects affected / exposed
    1 / 17 (5.88%)
    0 / 2 (0.00%)
         occurrences all number
    1
    0
    Tonsillitis bacterial
         subjects affected / exposed
    1 / 17 (5.88%)
    0 / 2 (0.00%)
         occurrences all number
    1
    0
    Urinary tract infection
         subjects affected / exposed
    3 / 17 (17.65%)
    0 / 2 (0.00%)
         occurrences all number
    4
    0
    Metabolism and nutrition disorders
    Decreased appetite
         subjects affected / exposed
    3 / 17 (17.65%)
    0 / 2 (0.00%)
         occurrences all number
    5
    0
    Hypoalbuminaemia
         subjects affected / exposed
    1 / 17 (5.88%)
    0 / 2 (0.00%)
         occurrences all number
    1
    0
    Hypocalcaemia
         subjects affected / exposed
    1 / 17 (5.88%)
    0 / 2 (0.00%)
         occurrences all number
    1
    0
    Hyponatraemia
         subjects affected / exposed
    2 / 17 (11.76%)
    0 / 2 (0.00%)
         occurrences all number
    2
    0

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    11 Mar 2020
    • Introduction of additional safety information and toxicity management guidelines regarding the delayed hypersensitivity for combination of domatinostat with anti-PD-(L)1 antibodies • Updates to Schedule of Activities to clarify study timepoints • Other administrative changes to clarify wording in protocol • All tables in protocol numbered

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    The study was prematurely terminated based on a sponsor’s data review of 2 ongoing clinical trials with domatinostat, concluding that it is very unlikely that domatinostat may provide significant benefit to these patients due to lack of efficacy.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 12:35:26 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA